Immutep Ltd started a second Phase trial for Efti in Soft Tissue Sarcoma

Immutep Ltd (ASX: IMU) announced the start of a second Phase study in up to 40 soft tissue sarcoma patients before surgery, employing eftilagimod alpha (efti), a soluble LAG-3 protein and MHC Class II agonist, in combination with pembrolizumab and radiation.

Efti targets antigen-presenting cells to combat cancer and specifically activates them via MHC Class II molecules. This results in the proliferation of CD8+ cytotoxic T cells that can be equipped with radiotherapy-induced tumour antigens. In the immunosuppressed tumor microenvironment (TME) of STS, the combination of efti with radiation and the anti-PD-1 treatment KEYTRUDA® has the potential to trigger a powerful anti-tumor immune response. Soft tissue sarcoma patients have a poor prognosis and a significant unmet medical need.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com